ArticleMolecular and clinical oncology2016

Efficacy of first-line erlotinib in non-small cell lung cancer patients undergoing dose reduction and those with a low body surface area: A population-based observational study by the Ibaraki Thoracic Integrative (POSITIVE) Research Group.

Masaharu Inagaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.